跳至主要内容
临床试验/EUCTR2007-007161-20-BG
EUCTR2007-007161-20-BG进行中(未招募)不适用

Comparable efficacy and safety profiles of daily injection of BK0023 and filgrastim (Neupogen®) in chemotherapy-induced neutropenia: a multinational, multicenter, investigator blind, randomised, parallel group study in women with breast cancer

BIO-KER S.R.0 个研究点目标入组 288 人开始时间: 2008年12月30日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
288

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Women aged =18 years
  • Subjects willing and able to give written informed consent
  • Diagnosis of high-risk stage II or stage III/IV breast cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status = 2
  • Subjects chemotherapy naïve or adjuvant therapy only and/or only one chemotherapy regimen for metastatic disease
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Absolute neutrophil count < 1.5 x109/L; platelet count < 100 x109/L and
  • haemoglobin < 10 g/dl
  • Received systemic anti-infective treatment within 72h of chemotherapy
  • Prior bone marrow or stem cell transplantation
  • Total lifetime exposure to doxorubicin > 240 mg/m2 or epirubicin > 600
  • Subject of child bearing potential is evidently pregnant (eg, positive HCG
  • test) or is breast feeding
  • Subject of child bearing potential or partner of subject is not using or
  • refuses to use adequate contraceptive precautions
  • Previous exposure to G-CSF

研究者

发起方
BIO-KER S.R.

相似试验